These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

297 related articles for article (PubMed ID: 19789217)

  • 41. Retrospective analysis of antitumor effects of zoledronic acid in breast cancer patients with bone-only metastases.
    Niikura N; Liu J; Hayashi N; Palla SL; Tokuda Y; Hortobagyi GN; Ueno NT; Theriault RL
    Cancer; 2012 Apr; 118(8):2039-47. PubMed ID: 22139648
    [TBL] [Abstract][Full Text] [Related]  

  • 42. The in vitro anti-tumour activity of zoledronic acid and docetaxel at clinically achievable concentrations in prostate cancer.
    Morgan C; Lewis PD; Jones RM; Bertelli G; Thomas GA; Leonard RC
    Acta Oncol; 2007; 46(5):669-77. PubMed ID: 17562444
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Zoledronic acid significantly improves pain scores and quality of life in breast cancer patients with bone metastases: a randomised, crossover study of community vs hospital bisphosphonate administration.
    Wardley A; Davidson N; Barrett-Lee P; Hong A; Mansi J; Dodwell D; Murphy R; Mason T; Cameron D
    Br J Cancer; 2005 May; 92(10):1869-76. PubMed ID: 15870721
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Bone-Bound Bisphosphonates Inhibit Proliferation of Breast Cancer Cells.
    Park YE; Bava U; Lin JM; Cornish J; Naot D; Reid IR
    Calcif Tissue Int; 2019 Nov; 105(5):497-505. PubMed ID: 31324954
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Radiological changes following second-line zoledronic acid treatment in breast cancer patients with bone metastases.
    Amir E; Whyne C; Freedman OC; Fralick M; Kumar R; Hardisty M; Clemons M
    Clin Exp Metastasis; 2009; 26(5):479-84. PubMed ID: 19266291
    [TBL] [Abstract][Full Text] [Related]  

  • 46. The combined use of Camellia sinensis and metronomic zoledronic acid in a breast cancer-induced osteolysis mouse model.
    Luo KW; Ko CH; Yue GG; Gao S; Lee JK; Li G; Fung KP; Leung PC; Evdokiou A; Lau CB
    J Cancer Res Clin Oncol; 2015 Jun; 141(6):1025-36. PubMed ID: 25431338
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Phase II trial evaluating the palliative benefit of second-line zoledronic acid in breast cancer patients with either a skeletal-related event or progressive bone metastases despite first-line bisphosphonate therapy.
    Clemons MJ; Dranitsaris G; Ooi WS; Yogendran G; Sukovic T; Wong BY; Verma S; Pritchard KI; Trudeau M; Cole DE
    J Clin Oncol; 2006 Oct; 24(30):4895-900. PubMed ID: 17001071
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Zoledronic acid and survival in breast cancer patients with bone metastases and elevated markers of osteoclast activity.
    Lipton A; Cook RJ; Major P; Smith MR; Coleman RE
    Oncologist; 2007 Sep; 12(9):1035-43. PubMed ID: 17914073
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Evaluation of the combined use of metronomic zoledronic acid and Coriolus versicolor in intratibial breast cancer mouse model.
    Ko CH; Yue GG; Gao S; Luo KW; Siu WS; Shum WT; Shiu HT; Lee JK; Li G; Leung PC; Evdokiou A; Lau CB
    J Ethnopharmacol; 2017 May; 204():77-85. PubMed ID: 28412218
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Oestrogen receptor positive breast cancer metastasis to bone: inhibition by targeting the bone microenvironment in vivo.
    Holen I; Walker M; Nutter F; Fowles A; Evans CA; Eaton CL; Ottewell PD
    Clin Exp Metastasis; 2016 Mar; 33(3):211-24. PubMed ID: 26585891
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Adoptive transfer of ex vivo expanded Vγ9Vδ2 T cells in combination with zoledronic acid inhibits cancer growth and limits osteolysis in a murine model of osteolytic breast cancer.
    Zysk A; DeNichilo MO; Panagopoulos V; Zinonos I; Liapis V; Hay S; Ingman W; Ponomarev V; Atkins G; Findlay D; Zannettino A; Evdokiou A
    Cancer Lett; 2017 Feb; 386():141-150. PubMed ID: 27865798
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Reactive oxygen species and autophagy associated apoptosis and limitation of clonogenic survival induced by zoledronic acid in salivary adenoid cystic carcinoma cell line SACC-83.
    Ge XY; Yang LQ; Jiang Y; Yang WW; Fu J; Li SL
    PLoS One; 2014; 9(6):e101207. PubMed ID: 24963720
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Potentiated suppression of Dickkopf-1 in breast cancer by combined administration of the mevalonate pathway inhibitors zoledronic acid and statins.
    Göbel A; Browne AJ; Thiele S; Rauner M; Hofbauer LC; Rachner TD
    Breast Cancer Res Treat; 2015 Dec; 154(3):623-31. PubMed ID: 26515701
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Inhibition on the growth of human MDA-MB-231 breast cancer cells in vitro and tumor growth in a mouse xenograft model by Se-containing polysaccharides from Pyracantha fortuneana.
    Yuan C; Wang C; Wang J; Kumar V; Anwar F; Xiao F; Mushtaq G; Liu Y; Kamal MA; Yuan D
    Nutr Res; 2016 Nov; 36(11):1243-1254. PubMed ID: 27865619
    [TBL] [Abstract][Full Text] [Related]  

  • 55. KRAS-mutation status dependent effect of zoledronic acid in human non-small cell cancer preclinical models.
    Kenessey I; Kói K; Horváth O; Cserepes M; Molnár D; Izsák V; Dobos J; Hegedűs B; Tóvári J; Tímár J
    Oncotarget; 2016 Nov; 7(48):79503-79514. PubMed ID: 27780929
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Oral ibandronate is as active as intravenous zoledronic acid for reducing bone turnover markers in women with breast cancer and bone metastases.
    Body JJ; Lichinitser M; Tjulandin S; Garnero P; Bergström B
    Ann Oncol; 2007 Jul; 18(7):1165-71. PubMed ID: 17442659
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Zoledronic acid versus pamidronate in the treatment of skeletal metastases in patients with breast cancer or osteolytic lesions of multiple myeloma: a phase III, double-blind, comparative trial.
    Rosen LS; Gordon D; Kaminski M; Howell A; Belch A; Mackey J; Apffelstaedt J; Hussein M; Coleman RE; Reitsma DJ; Seaman JJ; Chen BL; Ambros Y
    Cancer J; 2001; 7(5):377-87. PubMed ID: 11693896
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Aromatase inhibitor-induced bone loss increases the progression of estrogen receptor-negative breast cancer in bone and exacerbates muscle weakness in vivo.
    Wright LE; Harhash AA; Kozlow WM; Waning DL; Regan JN; She Y; John SK; Murthy S; Niewolna M; Marks AR; Mohammad KS; Guise TA
    Oncotarget; 2017 Jan; 8(5):8406-8419. PubMed ID: 28039445
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Zoledronic acid: a review of its use in breast cancer.
    Lyseng-Williamson KA
    Drugs; 2008; 68(18):2661-82. PubMed ID: 19093706
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Combined effects of a third-generation bisphosphonate, zoledronic acid with other anticancer agents against murine osteosarcoma.
    Horie N; Murata H; Kimura S; Takeshita H; Sakabe T; Matsui T; Maekawa T; Kubo T; Fushiki S
    Br J Cancer; 2007 Jan; 96(2):255-61. PubMed ID: 17242698
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.